Valerio Iebba

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2737762/publications.pdf Version: 2024-02-01



VALEDIO LEBRA

#	Article	IF	CITATIONS
1	Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer. Nature Medicine, 2022, 28, 315-324.	15.2	225
2	Cancer Induces a Stress lleopathy Depending on β-Adrenergic Receptors and Promoting Dysbiosis that Contributes to Carcinogenesis. Cancer Discovery, 2022, 12, 1128-1151.	7.7	44
3	Short-chain fatty acids promote the effect of environmental signals on the gut microbiome and metabolome in mice. Communications Biology, 2022, 5, .	2.0	16
4	Microbiota tryptophan metabolism induces aryl hydrocarbon receptor activation and improves alcohol-induced liver injury. Gut, 2021, 70, 1299-1308.	6.1	92
5	lleal immune tonus is a prognosis marker of proximal colon cancer in mice and patients. Cell Death and Differentiation, 2021, 28, 1532-1547.	5.0	11
6	Ketogenic diet and ketone bodies enhance the anticancer effects of PD-1 blockade. JCI Insight, 2021, 6, .	2.3	143
7	Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment. Cell Death and Differentiation, 2021, 28, 2778-2796.	5.0	72
8	Multifaceted modes of action of the anticancer probiotic Enterococcus hirae. Cell Death and Differentiation, 2021, 28, 2276-2295.	5.0	18
9	Profiling of Oral Microbiota and Cytokines in COVID-19 Patients. Frontiers in Microbiology, 2021, 12, 671813.	1.5	50
10	Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. Nature Medicine, 2021, 27, 1432-1441.	15.2	216
11	Lactobacillus iners and gasseri, Prevotella bivia and HPV Belong to the Microbiological Signature Negatively Affecting Human Reproduction. Microorganisms, 2021, 9, 39.	1.6	22
12	High abundance of genus Prevotella is associated with dysregulation of IFN-I and T cell response in HIV-1-infected patients. Aids, 2020, 34, 1467-1473.	1.0	14
13	Structural Variations of Vaginal and Endometrial Microbiota: Hints on Female Infertility. Frontiers in Cellular and Infection Microbiology, 2020, 10, 350.	1.8	67
14	Cross-reactivity between tumor MHC class l–restricted antigens and an enterococcal bacteriophage. Science, 2020, 369, 936-942.	6.0	217
15	Gut Bacteria Composition Drives Primary Resistance to Cancer Immunotherapy in Renal Cell Carcinoma Patients. European Urology, 2020, 78, 195-206.	0.9	192
16	Chemotherapy-induced ileal crypt apoptosis and the ileal microbiome shape immunosurveillance and prognosis of proximal colon cancer. Nature Medicine, 2020, 26, 919-931.	15.2	118
17	Physiologic colonic uptake of ¹⁸ F-FDG on PET/CT predicts immunotherapy response and gut microbiome diversity in patients with advanced non-small cell lung cancer (NSCLC) Journal of Clinical Oncology, 2020, 38, 9600-9600.	0.8	0
18	Nasal microbiota in RSV microbiota. , 2019, , .		2

VALERIO IEBBA

#	Article	IF	CITATIONS
19	Fecal Microbial Transplantation impact on gut microbiota composition and metabolome, microbial translocation and T-lymphocyte immune activation in recurrent Clostridium difficile infection patients. New Microbiologica, 2019, 42, 221-224.	0.1	7
20	Swimming and rafting of <i>E.coli</i> microcolonies at air–liquid interfaces. MicrobiologyOpen, 2018, 7, e00532.	1.2	7
21	Combining amplicon sequencing and metabolomics in cirrhotic patients highlights distinctive microbiota features involved in bacterial translocation, systemic inflammation and hepatic encephalopathy. Scientific Reports, 2018, 8, 8210.	1.6	63
22	1014 - Microbiota Composition, Metabolic Profiles and Inflammatory Host Response after Fecal Microbiota Transplantation (FMT) for Recurrent Clostridium Difficile Infection. Does Proteobacteria Abundance Predict the Response to FMT?. Gastroenterology, 2018, 154, S-192.	0.6	0
23	Rebuilding the Gut Microbiota Ecosystem. International Journal of Environmental Research and Public Health, 2018, 15, 1679.	1.2	231
24	Gut microbiome composition to predict resistance in renal cell carcinoma (RCC) patients on nivolumab Journal of Clinical Oncology, 2018, 36, 4519-4519.	0.8	4
25	Behaviour of Bdellovibrio bacteriovorus in the presence of Gram-positive Staphylococcus aureus. New Microbiologica, 2018, 41, 145-152.	0.1	16
26	Optimizing an array of self adapted temperature modulated metal oxide sensors for biomedical application. , 2017, , .		1
27	Exposure of E. coli to DNA-Methylating Agents Impairs Biofilm Formation and Invasion of Eukaryotic Cells via Down Regulation of the N-Acetylneuraminate Lyase NanA. Frontiers in Microbiology, 2016, 7, 147.	1.5	13
28	Mo1927 Mucosa-Associated Microbiota and Promoter Methylation Status of Genes Involved in Immune Response in Crohn's Disease Patients. Gastroenterology, 2016, 150, S818.	0.6	0
29	Uncovering oral Neisseria tropism and persistence using metagenomic sequencing. Nature Microbiology, 2016, 1, 16070.	5.9	68
30	Protective Role of Postbiotic Mediators Secreted by Lactobacillus rhamnosus GG Versus Lipopolysaccharide-induced Damage in Human Colonic Smooth Muscle Cells. Journal of Clinical Gastroenterology, 2016, 50, S140-S144.	1.1	38
31	Bacterial Biofilm in Salivary Gland Stones. Otolaryngology - Head and Neck Surgery, 2016, 154, 449-453.	1.1	17
32	What is new about diet in hepatic encephalopathy. Metabolic Brain Disease, 2016, 31, 1289-1294.	1.4	30
33	Gut microbiota related to Giardia duodenalis, Entamoeba spp. and Blastocystis hominis infections in humans from Côte d'lvoire. Journal of Infection in Developing Countries, 2016, 10, 1035-1041.	0.5	89
34	Eubiosis and dysbiosis: the two sides of the microbiota. New Microbiologica, 2016, 39, 1-12.	0.1	109
35	OPâ€3 THE PROTECTIVE ROLE OF LACTOBACILLUS RHAMNOSUS GGâ€DERIVED FACTORS AGAINST LPSâ€INDL DAMAGE OF HUMAN COLONIC SMOOTH MUSCLE CELLS Journal of Pediatric Gastroenterology and Nutrition, 2015, 61, 509-510.	ICED 0.9	1
36	Su1861 Postbiotic Protective Activity of Lactobacillus Rhamnosus GG-Derived Factors on Pathogen Lipopolysaccharide (LPS)-Induced Damage of Human Colonic Smooth Muscle. Gastroenterology, 2015, 148, S-536.	0.6	0

VALERIO IEBBA

#	Article	IF	CITATIONS
37	Outbreak of Achromobacter xylosoxidans in an Italian Cystic fibrosis center: genome variability, biofilm production, antibiotic resistance, and motility in isolated strains. Frontiers in Microbiology, 2014, 5, 138.	1.5	46
38	Bdellovibrio bacteriovorus directly attacks Pseudomonas aeruginosa and Staphylococcus aureus Cystic fibrosis isolates. Frontiers in Microbiology, 2014, 5, 280.	1.5	74
39	Microbiota and the gut-liver axis: Bacterial translocation, inflammation and infection in cirrhosis. World Journal of Gastroenterology, 2014, 20, 16795.	1.4	187
40	<i>Escherichia coli</i> Population-Based Study in Pediatric Crohn's Disease. Advances in Microbiology, 2014, 04, 886-889.	0.3	1
41	Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Allelic Variants Relate to Shifts in Faecal Microbiota of Cystic Fibrosis Patients. PLoS ONE, 2013, 8, e61176.	1.1	83
42	Higher Prevalence and Abundance of Bdellovibrio bacteriovorus in the Human Gut of Healthy Subjects. PLoS ONE, 2013, 8, e61608.	1.1	93
43	Microevolution in <i>fimH</i> Gene of Mucosa-Associated Escherichia coli Strains Isolated from Pediatric Patients with Inflammatory Bowel Disease. Infection and Immunity, 2012, 80, 1408-1417.	1.0	49
44	Gut Microbiota and the Immune System: An Intimate Partnership in Health and Disease. International Journal of Immunopathology and Pharmacology, 2012, 25, 823-833.	1.0	30
45	Plasmid-mediated fluoroquinolone resistance determinants in Escherichia coli from community uncomplicated urinary tract infection in an area of high prevalence of quinolone resistance. European Journal of Clinical Microbiology and Infectious Diseases, 2012, 31, 1917-1921.	1.3	21
46	A potential role of <i>Escherichia coli</i> pathobionts in the pathogenesis of pediatric inflammatory bowel disease. Canadian Journal of Microbiology, 2012, 58, 426-432.	0.8	29
47	Assessment Of Daily Physical Activity In Patients With Cystic Fibrosis. , 2012, , .		0
48	Influence of oral conditions on colonization by highly toxigenic <i>Staphylococcus aureus</i> strains. Oral Diseases, 2012, 18, 402-409.	1.5	20
49	Diffusion of meticillin-resistant Staphylococcus aureus USA300 strains in central Italy. International Journal of Antimicrobial Agents, 2011, 37, 339-346.	1.1	9
50	Swimming with an Image. Physical Review Letters, 2011, 106, 038101.	2.9	217
51	Gut Microbiota and Pediatric Disease. Digestive Diseases, 2011, 29, 531-539.	0.8	34
52	Microbiological and molecular characterization of nosocomial and community Staphylococcus aureus isolates. Epidemiology and Infection, 2011, 139, 613-622.	1.0	9
53	JC Viral Reactivation in a Pediatric Patient with Crohn's Disease. International Journal of Immunopathology and Pharmacology, 2010, 23, 955-959.	1.0	8
54	A distinctive 'microbial signature' in celiac pediatric patients. BMC Microbiology, 2010, 10, 175.	1.3	201

VALERIO IEBBA

#	Article	IF	CITATIONS
55	<i>Achromobacter xylosoxidans</i> Genomic Characterization and Correlation of Randomly Amplified Polymorphic DNA Profiles of Cystic Fibrosis Patients. Journal of Clinical Microbiology, 2010, 48, 1035-1039.	1.8	14
56	Bacterial ratchet motors. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 9541-9545.	3.3	559
57	T1811 Dominant Intestinal Mucosa-Associated Microbiota in Pediatric Patients With Inflammatory Bowel Disease. Gastroenterology, 2010, 138, S-583-S-584.	0.6	0
58	Dominant genotypes in mucosa-associated Escherichia coli strains from pediatric patients with inflammatory bowel disease. Inflammatory Bowel Diseases, 2009, 15, 661-672.	0.9	38
59	Effect of lactoferricin on fluoroquinolone susceptibility of uropathogenic Escherichia coli. Journal of Antibiotics, 2009, 62, 109-111.	1.0	5
60	The Microbiota in Inflammatory Bowel Disease in Different Age Groups. Digestive Diseases, 2009, 27, 252-258.	0.8	56
61	T1274 Dominant Mucosa-Associated Microbiota in Celiac Children At Diagnosis and After GFD. Gastroenterology, 2008, 134, A-520.	0.6	0
62	W1188 Dominant Genotypes in Mucosa-Associated Escherichia coli Strains from Pediatric Patients with Inflammatory Bowel Disease. Gastroenterology, 2008, 134, A-651.	0.6	0
63	Virulence Traits in Escherichia Coli Strains Isolated from Outpatients with Urinary Tract Infections. International Journal of Immunopathology and Pharmacology, 2008, 21, 715-723.	1.0	2